Precision radiation: could a special scan improve prostate cancer treatment?

NCT ID NCT04402151

Recruiting now Disease control Sponsor: Weill Medical College of Cornell University Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase II trial is testing whether using a special PET/MR scan (PSMA) to guide radiation therapy can improve outcomes for men with high-risk prostate cancer. Fifty participants will receive targeted radiation boosts to areas identified by the scan. The main goal is to see if this approach increases the number of men who remain cancer-free two years after treatment.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Gallium-68 labeled PSMA-HBED-CC (a radioactive tracer for imaging)
What this could lead to: If successful, this approach could offer a more precise radiation treatment for high-risk prostate cancer, potentially reducing recurrence rates.
What could go wrong: This is a small, early-phase trial with only 50 participants. It may not show a significant benefit over standard treatments, and there are risks from radiation exposure.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HIGH RISK PROSTATE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

prostate cancer prostate carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PROSTATE CANCER

Contacts and locations

Locations

Weill Cornell Medicine
RECRUITING

New York, New York, 10065', United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.